Argenx Shares Decline Following Investigation Notice
ARGX stock dropped over 10% after a Phase 3 trial was discontinued due to a futility finding. Investor group SueWallSt announced a pending investigation into the company.
Argenx SE (NASDAQ: ARGX) saw its stock price fall more than 10% in pre-market trading on Friday, October 8, 2026. The decline followed news that a pending Phase 3 clinical trial for the company has been discontinued.
The discontinuation was reportedly due to a futility finding, which suggests that the drug candidate is unlikely to meet its primary endpoints. While specific details of the futility assessment have not been disclosed, such findings typically indicate that further investment in the trial is not warranted.
SueWallSt, a law firm representing investors, has announced that it is launching an investigation into argenx. The investigation will examine the company's actions and disclosures surrounding the trial's discontinuation and its impact on the stock price, focusing on whether investors received adequate and timely information.
Argenx is a biopharmaceutical company developing therapies for severe autoimmune diseases. The stock's reaction highlights the inherent risks in drug development and the sensitivity of biotechnology stock valuations to clinical trial outcomes.